Post-therapy ctDNA clearance predicts better response and survival in GEJ adenocarcinoma (40) ctDNA profiling (TP53, EGFR, KRAS) aids personalized treatment (41). Here, KRAS is linked to gastroesophageal junction adenocarcinoma.